导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.61% | 3531/4773 |
| 近一周 | -2.80% | 3130/5462 |
| 近一月 | -3.89% | 2056/5421 |
| 近一季 | -8.74% | 2936/5209 |
| 近半年 | -11.70% | 3741/4920 |
| 近一年 | -3.54% | 3062/4366 |
| 近两年 | 56.10% | 1305/2954 |
| 近三年 | 24.79% | 1288/2253 |
| 成立以来 | -34.30% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.33% 2238/4961 |
4.20% 2917/5312 |
- - |
- - |
| 2025 | 23.33% 1884/4813 |
-1.85% 2796/3635 |
3.00% 1210/4076 |
22.23% 1668/4524 |
-0.19% 2407/4813 |
| 2024 | 10.46% 1408/3463 |
0.93% 921/2808 |
-11.54% 2547/3014 |
18.36% 1019/3129 |
4.53% 700/3463 |
| 2023 | -3.49% 641/2656 |
4.47% 944/2280 |
0.03% 349/2385 |
-5.84% 1384/2515 |
-1.92% 391/2655 |
| 2022 | -13.51% 332/2207 |
-9.73% 340/1919 |
0.89% 1519/2016 |
-7.32% 123/2113 |
2.47% 928/2208 |
| 2021 | 11.03% 408/1822 |
-5.20% 910/1255 |
7.62% 676/1330 |
10.60% 118/1466 |
-1.61% 1376/1822 |
| 2020 | 26.98% 590/1250 |
-1.90% 247/1028 |
19.08% 312/1067 |
3.77% 970/1164 |
4.75% 829/1184 |
| 2019 | 26.02% 586/1092 |
24.10% 530/754 |
-5.97% 490/804 |
1.28% 417/850 |
6.64% 577/918 |
| 2018 | -37.08% 594/834 |
- - |
- - |
- - |
-13.69% 548/691 |
| 2017 | -12.14% 549/714 |
- - |
- - |
- - |
- - |
| 2016 | -20.13% 440/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达中证万得并购重组(LOF) VS. 长安沪深300非周期A(740101) |